Reimbursement Review Reports

The latest CADTH Reimbursement Review reports are posted to this page. CADTH reimbursement reviews are comprehensive assessments of the clinical effectiveness and cost-effectiveness, as well as patient and clinician perspectives, of a drug or drug class. The assessments inform non-binding recommendations that help guide the reimbursement decisions of Canada's federal, provincial, and territorial governments, with the exception of Quebec. Implementation advice and funding algorithms are provided where applicable.

Brand Name Generic Name Therapeutic Area Recommendation Type Sort ascending Project Status Date Submission Received Date Recommendation Issued
Myalepta metreleptin Leptin deficiency in lipodystrophy Active
Adtralza tralokinumab atopic dermatitis (AD) Active
TBC leniolisib Activated phosphoinositide 3 kinase delta syndrome Received
Repatha evolocumab Primary hyperlipidemia Active
TBC sotatercept Pulmonary arterial hypertension (WHO group 1) Active
Elrexfio elranatamab Relapsed or refractory multiple myeloma Active
Jemperli dostarlimab Endometrial cancer Active
Libtayo cemiplimab Locally advanced or metastatic NSCLC (first line) Active
Epkinly epcoritamab Relapsed or refractory diffuse large B-cell lymphoma Active
Remsima infliximab Crohn’s disease Active